End-of-day quote
Taiwan S.E.
23:00:00 30/06/2024 BST
5-day change
1st Jan Change
52.2
TWD
-0.57%
+4.71%
-9.06%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction announced on March 11, 2024
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced a private placement of not more than 15,512,000 common shares on March 11, 2024. The transaction has been approved by the shareholders of the company.
On the same day, Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Elects Hou-Kai as Vice Chairman
05-30
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Approves Cash Dividend for the Year 2023
05-30
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-15
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
03-28
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction announced on March 11, 2024
03-10
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-13
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
11/08/23
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022, Payable on August 18, 2023
27/06/23
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022
30/05/23
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
31/03/23
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced a financing transaction
06/03/23
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
10/11/22
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
11/08/22
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Dividend, Payable on August 18, 2022
28/06/22
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Appointment of Kuan Arthur¡G as Independent Director
25/05/22
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Approves Cash Dividend for 2021
25/05/22
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
13/05/22
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
31/03/22
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
11/11/21
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
13/08/21
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend, Payable on August 18, 2021
01/07/21
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
14/05/21
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
30/03/21
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
12/11/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
More about the company
Last Close Price
52.2
TWD
Average target price
48
TWD
Spread / Average Target
-8.05%
Consensus
1st Jan change
Capi.
-9.06% 125M +2.08% 95.18B -0.13% 37.55B -10.21% 33.75B +77.76% 28.2B -14.50% 15.63B -3.14% 13.63B -12.76% 11.5B +181.73% 10.81B -53.92% 9.23B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1